Literature DB >> 26926205

Metabolic Syndrome and the Risk of Mild Cognitive Impairment and Progression to Dementia: Follow-up of the Singapore Longitudinal Ageing Study Cohort.

Tze Pin Ng1, Liang Feng1, Ma Shwe Zin Nyunt1, Lei Feng1, Qi Gao1, May Li Lim1, Simon L Collinson2, Mei Sian Chong3, Wee Shiong Lim3, Tih Shih Lee4, Philip Yap5, Keng Bee Yap6.   

Abstract

IMPORTANCE: The association of the metabolic syndrome (MetS) and component cardiovascular risk factors with the risk of developing mild cognitive impairment (MCI) and MCI progression to dementia is not well established.
OBJECTIVE: To investigate the association of the MetS and its component cardiovascular risk factors with the incidence of MCI and its progression to dementia. DESIGN, SETTING, AND PARTICIPANTS: Prospective longitudinal study from September 1, 2003, through December 31, 2009, in communities in 5 districts in the South East region of Singapore. Study participants were a population-based sample of 1519 cognitively normal adults 55 years and older. MAIN OUTCOMES AND MEASURES: Prespecified outcomes were incident MCI and MCI progression to dementia.
RESULTS: The study cohort comprised 1519 participants. Their mean (SD) age was 64.9 (6.8) years, and 64.8% (n = 984) were female. Baseline characteristics associated with an increased risk of incident MCI were MetS (hazard ratio [HR], 1.46; 95% CI, 1.02-2.09), central obesity (HR, 1.41; 95% CI, 1.01-1.98), diabetes mellitus (HR, 2.84; 95% CI, 1.92-4.19), dyslipidemia (HR, 1.48; 95% CI, 1.01-2.15), and 3 or more component cardiovascular risk factors (HR, 1.58; 95% CI, 1.13-2.33). Baseline characteristics associated with an increased risk of MCI progression to dementia were MetS (HR, 4.25; 95% CI, 1.29-14.00), diabetes mellitus (HR, 2.47; 95% CI, 1.92-4.19), and 3 or more component cardiovascular risk factors (HR, 4.92; 95% CI, 1.39-17.4). CONCLUSIONS AND RELEVANCE: The MetS was associated with an increased incidence of MCI and progression to dementia. Identifying individuals with diabetes mellitus or the MetS with or without MCI is a promising approach in early interventions to prevent or slow progression to dementia.

Entities:  

Mesh:

Year:  2016        PMID: 26926205     DOI: 10.1001/jamaneurol.2015.4899

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  54 in total

1.  The Association of Late-Life Diabetes Status and Hyperglycemia With Incident Mild Cognitive Impairment and Dementia: The ARIC Study.

Authors:  Andreea M Rawlings; A Richey Sharrett; Marilyn S Albert; Josef Coresh; B Gwen Windham; Melinda C Power; David S Knopman; Keenan Walker; Sheila Burgard; Thomas H Mosley; Rebecca F Gottesman; Elizabeth Selvin
Journal:  Diabetes Care       Date:  2019-05-21       Impact factor: 19.112

2.  Dementia: is the biopsychosocial model vindicated?

Authors:  Steve Iliffe; Jill Manthorpe
Journal:  Br J Gen Pract       Date:  2017-08       Impact factor: 5.386

Review 3.  Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease.

Authors:  Heeyoung Lee; EunYoung Kim
Journal:  Arch Pharm Res       Date:  2020-09-09       Impact factor: 4.946

4.  Associations of sleep durations and sleep-related parameters with metabolic syndrome among older Chinese adults.

Authors:  Yu-Xi Qian; Jing-Hong Liu; Qing-Hua Ma; Hong-Peng Sun; Yong Xu; Chen-Wei Pan
Journal:  Endocrine       Date:  2019-08-31       Impact factor: 3.633

Review 5.  Diagnostic imaging in the management of patients with metabolic syndrome.

Authors:  Seo Rin Kim; Lilach O Lerman
Journal:  Transl Res       Date:  2017-11-22       Impact factor: 7.012

6.  The Prevalence and Determinants of Cognitive Deficits and Traditional Diabetic Complications in the Severely Obese.

Authors:  Brian C Callaghan; Evan L Reynolds; Mousumi Banerjee; Ericka Chant; Emily Villegas-Umana; Thomas W Gardner; Kristen Votruba; Bruno Giordani; Rodica Pop-Busui; Subramaniam Pennathur; Eva L Feldman
Journal:  Diabetes Care       Date:  2020-01-13       Impact factor: 19.112

7.  Informal Caregiving, Poor Mental Health, and Subjective Cognitive Decline: Results From a Population-Based Sample.

Authors:  Monique J Brown; Steven A Cohen
Journal:  J Gerontol Nurs       Date:  2020-12-01       Impact factor: 1.254

8.  Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis.

Authors:  Ruth Peters; Sevil Yasar; Craig S Anderson; Shea Andrews; Riitta Antikainen; Hisatomi Arima; Nigel Beckett; Joanne C Beer; Anne Suzanne Bertens; Andrew Booth; Martin van Boxtel; Carol Brayne; Henry Brodaty; Michelle C Carlson; John Chalmers; Maria Corrada; Steven DeKosky; Carol Derby; Roger A Dixon; Françoise Forette; Mary Ganguli; Willem A van Gool; Antonio Guaita; Ann M Hever; David B Hogan; Carol Jagger; Mindy Katz; Claudia Kawas; Patrick G Kehoe; Sirkka Keinanen-Kiukaanniemi; Rose Ann Kenny; Sebastian Köhler; Setor K Kunutsor; Jari Laukkanen; Colleen Maxwell; G Peggy McFall; Tessa van Middelaar; Eric P Moll van Charante; Tze-Pin Ng; Jean Peters; Iris Rawtaer; Edo Richard; Kenneth Rockwood; Lina Rydén; Perminder S Sachdev; Ingmar Skoog; Johan Skoog; Jan A Staessen; Blossom C M Stephan; Sylvain Sebert; Lutgarde Thijs; Stella Trompet; Phillip J Tully; Christophe Tzourio; Roberta Vaccaro; Eeva Vaaramo; Erin Walsh; Jane Warwick; Kaarin J Anstey
Journal:  Neurology       Date:  2019-12-11       Impact factor: 9.910

9.  Type 2 Diabetes Mellitus Is Associated with the Risk of Cognitive Impairment: a Meta-Analysis.

Authors:  Xiaojun Zhang; Xiaolu Jiang; Sufang Han; Qianqi Liu; Jing Zhou
Journal:  J Mol Neurosci       Date:  2019-04-04       Impact factor: 3.444

10.  Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores.

Authors:  Maureen Leehey; Sheng Luo; Saloni Sharma; Anne-Marie A Wills; Jacquelyn L Bainbridge; Pei Shieen Wong; David K Simon; Jay Schneider; Yunxi Zhang; Adriana Pérez; Rohit Dhall; Chadwick W Christine; Carlos Singer; Franca Cambi; James T Boyd
Journal:  Neurology       Date:  2017-09-29       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.